Department of Radiation Oncology, University of California, Los Angeles.
Palo Alto Veterans Affairs Hospital, Palo Alto, CA.
Am J Clin Oncol. 2021 Mar 1;44(3):99-104. doi: 10.1097/COC.0000000000000792.
To investigate the benefit of postoperative radiotherapy (PORT) for low-volume (pN1) nodal disease after resection of oral cavity squamous cell carcinoma.
The National Cancer Database was queried for adults with nonmetastatic squamous cell carcinoma of the oral cavity treated by surgical resection with pathologic stage T1-2 N0-2 (American Joint Committee on Cancer 7th edition) and with the maximal exclusion of standard indications for PORT. Overall survival was compared within pN1 for observation versus PORT and then compared for pN1 versus pN0 and versus pN2 stratified by receipt of observation or PORT. Multivariable Cox regression was used to adjust for potential confounders between PORT and survival, including comorbidity and age.
Overall 5017 pN0, 530 pN1, and 253 pN2 patients were identified, of whom 9%, 35%, and 64% received PORT, respectively. Within the pN1 cohort, PORT was associated with improved survival versus observation (adjusted hazard ratio, 0.66; 95% confidence interval, 0.46-0.97; P=0.03). Among observed patients, the prognosis of pN1 was equivalent to pN2 and inferior to pN0; in contrast, among patients treated with PORT, the prognosis of pN1 was equivalent to pN0 and superior to pN2. Without PORT, pN1 remained an adverse risk factor relative to pN0 regardless of the depth of invasion, lymph node size, lymph node location, and extent of lymph node dissection.
PORT was associated with a survival benefit compared with observation. Notably, pN1 was an adverse risk factor relative to pN0 if, and only if, patients did not receive PORT, suggesting pN1 by itself may be an indication for PORT.
探讨口腔鳞状细胞癌切除术后低容量(pN1)淋巴结疾病行术后放疗(PORT)的获益。
本研究在美国国家癌症数据库中检索了经手术切除治疗、病理分期为 T1-2 N0-2(美国癌症联合委员会第 7 版)且排除 PORT 标准适应证的最大局限性的非转移性口腔鳞状细胞癌成年患者。对观察与 PORT 治疗下的 pN1 患者的总生存率进行了比较,然后对 pN1 与 pN0 以及 pN2 患者(根据是否接受观察或 PORT 治疗进行分层)进行了比较。多变量 Cox 回归用于调整 PORT 与生存之间的潜在混杂因素,包括合并症和年龄。
共确定了 5017 例 pN0、530 例 pN1 和 253 例 pN2 患者,分别有 9%、35%和 64%的患者接受了 PORT。在 pN1 队列中,与观察相比,PORT 治疗与生存率提高相关(调整后的危险比为 0.66;95%置信区间为 0.46-0.97;P=0.03)。在观察患者中,pN1 的预后与 pN2 相当,劣于 pN0;相比之下,在接受 PORT 治疗的患者中,pN1 的预后与 pN0 相当,优于 pN2。如果患者未接受 PORT,pN1 仍然是相对于 pN0 的不良危险因素,而与肿瘤浸润深度、淋巴结大小、淋巴结位置和淋巴结清扫范围无关。
与观察相比,PORT 治疗与生存获益相关。值得注意的是,如果患者未接受 PORT,pN1 相对于 pN0 是一个不良危险因素,这表明 pN1 本身可能是 PORT 的适应证。